{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:49:08Z","timestamp":1792144148385,"version":"4.4.0"},"reference-count":44,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm driven by overexpression of colony\u2010stimulating factor 1 (CSF1). We performed a meta\u2010analysis of the efficacy and safety of CSF1 receptor inhibitors (CSF1Ri) versus placebo in recurrent or unresectable TGCT, defined as symptomatic disease for which surgery would cause worsening functional limitation or severe morbidity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed\/MEDLINE, Scopus, Google Scholar, CENTRAL, and the ClinicalTrials.gov registry were searched from inception to March 25, 2026 for phase III randomized controlled trials (RCTs) comparing any CSF1Ri with placebo in adults with histologically confirmed TGCT. The primary outcome was objective response rate (ORR); secondary outcomes were physical function (PROMIS\u2010PF), range of motion (ROM), pain, health\u2010related quality of life (EQ\u2010VAS), and Grade 3 or higher adverse events. Risk of bias (RoB 2) and certainty (GRADE) were assessed; estimates were pooled using random\u2010effects models (RevMan 5.4.1), with fixed\u2010effect, Hartung\u2013Knapp\u2013Sidik\u2013Jonkman, risk\u2010difference, and leave\u2010one\u2010out sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three RCTs were included (ENLIVEN, MOTION, MANEUVER;\n                      <jats:italic>n<\/jats:italic>\n                      = 337), all at low risk of bias. CSF1Ri significantly improved ORR (RR 25.55 [95% CI 6.43\u2013101.52]; risk difference 0.43 [0.36\u20130.50]), PROMIS\u2010PF (MD 3.81 [2.28\u20135.34]), relative ROM (MD 11.43 [6.53\u201316.34] percentage points), and EQ\u2010VAS (MD 7.63 [4.03\u201311.23]) (all\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0%,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001), and reduced pain (SMD \u22121.03 [\u22121.65 to \u22120.42];\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0009;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 76%). Grade 3 or higher adverse events were more frequent with CSF1Ri (RR 4.08 [2.31\u20137.21];\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001;\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 0%). Certainty was high for functional outcomes, moderate for ORR and Grade 3 or higher adverse events, and low for pain.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In recurrent or unresectable TGCT, CSF1Ri produce clinically meaningful improvements in tumor response, function, and quality of life compared with placebo, at the cost of more frequent severe adverse events, the nature of which differed between trials. The included trials did not compare agents directly, so the relative efficacy and safety of individual CSF1Ri remain uncertain.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ajco.70211","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:27:53Z","timestamp":1792142873000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of CSF1R Inhibitors for Recurrent or Unresectable Tenosynovial Giant Cell Tumor: A Systematic Review and Meta\u2010Analysis of Phase III Randomized Controlled Trials"],"prefix":"10.1111","author":[{"given":"Mehmood","family":"Ahmad","sequence":"first","affiliation":[{"name":"Jinnah Sindh Medical University  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanza","family":"Farhan","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar Ali","family":"Khan","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzala","family":"Amir","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Saad","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hammad","family":"Ali","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Nafay","family":"Ali","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bismah Azam","family":"Ali","sequence":"additional","affiliation":[{"name":"Dow Medical College Dow University of Health Sciences  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amna","family":"Farhan","sequence":"additional","affiliation":[{"name":"Shaheed Mohtarma Benazir Bhutto Medical College  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Asad","family":"Raza","sequence":"additional","affiliation":[{"name":"Jinnah Sindh Medical University  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.2017.1361126"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1445427"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31802b86f8"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010021\u201001820\u20106"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32060342"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3233\/TUB\u2010220005"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1012527"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0507321103"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201024\u20100103"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(15)00132\u20101"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388\u2010020\u201001536\u20100"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1530890"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26529"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.OA.25.00313"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)02602\u20109"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)30764\u20100"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)00885\u20107"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643\u2010016\u20100384\u20104"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/CORR.0000000000002335"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1297"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102288\u201014\u201025"},{"key":"e_1_2_13_26_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Deeks J. J.","year":"2023"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33312"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2520744"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/17453674.2021.1922161"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13244\u2010023\u201001367\u2010z"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912\u2010025\u201001679\u2010x"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051388"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955\u2010023\u201002215\u2010w"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.675523"},{"key":"e_1_2_13_35_1","volume-title":"TURALIO (Pexidartinib) Capsules, for Oral Use: Prescribing Information","author":"US Food and Drug Administration"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010025\u201017232\u20106"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1594585"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12712"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010023\u201002926\u20109"},{"key":"e_1_2_13_40_1","volume-title":"Turalio (Pexidartinib): Refusal of the Marketing Authorisation","author":"European Medicines Agency"},{"key":"e_1_2_13_41_1","volume-title":"Deciphera Receives European Commission Approval of ROMVIMZA (Vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)","author":"Ono Pharmaceutical Co., Ltd"},{"key":"e_1_2_13_42_1","volume-title":"Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor","author":"Merck KGaA"},{"key":"e_1_2_13_43_1","volume-title":"FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor","author":"Merck KGaA"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555\u2010026\u201010328\u2010z"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487\u2010025\u201000365\u2010z"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.70211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.70211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:27:55Z","timestamp":1792142875000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.70211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":44,"alternative-id":["10.1111\/ajco.70211"],"URL":"https:\/\/doi.org\/10.1111\/ajco.70211","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"2026-09-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ajco.70211"}}